Zoetis (ZTS)

Executive Summary

Zoetis Inc. (NYSE: ZTS) is the world’s largest animal health company, spun off from Pfizer in 2013. It discovers, develops, manufactures, and commercializes a broad portfolio of medicines, vaccines, diagnostics, and services for companion animals (dogs, cats, horses) and livestock (cattle, swine, poultry, fish). Operating in over 100 countries, Zoetis generates the majority of its revenue from parasiticides, vaccines, and anti-infectives, with a growing focus on dermatology and other therapeutics. The company’s scale, strong R&D pipeline, and deep relationships with veterinarians and producers provide a durable competitive advantage. Recent trends in pet humanization and global protein demand continue to support long-term growth. Zoetis demonstrates consistent financial performance, with steady revenue growth and robust margins driven by innovation and geographic expansion. Its companion animal segment benefits from new product launches and increased spending on pet healthcare, while the livestock segment is supported by productivity needs in emerging markets. Key risks include regulatory changes, generic competition, and disease outbreaks affecting livestock. Overall, Zoetis’s market leadership, diversified portfolio, and exposure to secular tailwinds position it well for sustained value creation.

Upcoming Catalysts (preview)

• Q3 2026FDA approval of novel monoclonal antibody for canine osteoarthritis70% success
• Q1 2027Launch of next-generation parasiticide for cats in the U.S.80% success
• Q3 2026Q3 2026 earnings beat driven by strong companion animal sales60% success